• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

华法林治疗的心房颤动患者的肾小球滤过率:来自瑞典 AURICULA 登记处的亚组分析。

Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden.

机构信息

Department for Coagulation Disorders, Skåne University Hospital, University of Lund, Malmö, Sweden.

出版信息

Thromb Res. 2011 Oct;128(4):341-5. doi: 10.1016/j.thromres.2011.04.022. Epub 2011 May 28.

DOI:10.1016/j.thromres.2011.04.022
PMID:21620441
Abstract

INTRODUCTION

Numerous associations between chronic kidney disease (CKD) and atrial fibrillation (AF) have been reported and patients with CKD on anticoagulation therapy have an increased risk of bleeding. Currently, new anticoagulant agents are emerging in clinical practice, some of which are excreted by the kidneys. The proportion of AF patients on anticoagulant treatment with reduced renal function is, however, unknown.

MATERIALS AND METHODS

Using AURICULA, a Swedish registry for anticoagulation, estimated glomerular filtration rate (eGFR) was investigated in AF patients on warfarin treatment (n = 2,603). The study group was compared with a healthy sample from the population (n = 2,261). Two different creatinine prediction equations were used for calculating eGFR: the Lund-Malmö (LM) and MDRD Study equation.

RESULTS

The fraction of AF patients with eGFR <30 and <45 ml/min/1.73 m(2) were 8.1% and 22.9% with the LM and 4.3% and 16.3% with the MDRD equation, respectively, and significantly higher than corresponding values in the reference population. GFR decreased with increasing age, where 11.4% and 5.6% of AF patients aged ≥ 75 years had eGFR <30 ml/min/1.73 m(2) according to the LM and MDRD equations, respectively.

CONCLUSIONS

Severe renal impairment is common among AF patients on anticoagulant treatment with warfarin, especially at higher ages. Monitoring of renal function should be implemented in clinical practice for AF patients treated with new anticoagulants eliminated by the kidneys.

摘要

简介

大量研究报道了慢性肾脏病(CKD)与心房颤动(AF)之间的诸多关联,接受抗凝治疗的 CKD 患者出血风险增加。目前,新的抗凝药物已在临床实践中应用,其中一些药物经肾脏排泄。然而,肾功能下降的 AF 患者接受抗凝治疗的比例尚不清楚。

材料和方法

利用瑞典抗凝登记处 AURICULA,对接受华法林治疗的 AF 患者(n = 2603)的估算肾小球滤过率(eGFR)进行了研究。将研究组与来自人群的健康样本(n = 2261)进行了比较。使用两种不同的肌酐预测方程计算 eGFR:隆德-马尔默(LM)和 MDRD 研究方程。

结果

根据 LM 和 MDRD 方程,eGFR <30 和 <45 ml/min/1.73 m2 的 AF 患者比例分别为 8.1%和 22.9%,4.3%和 16.3%,明显高于参考人群的相应值。eGFR 随年龄增加而降低,根据 LM 和 MDRD 方程,年龄≥75 岁的 AF 患者中,分别有 11.4%和 5.6%的患者 eGFR <30 ml/min/1.73 m2。

结论

接受华法林抗凝治疗的 AF 患者中严重肾功能不全较为常见,尤其是年龄较大的患者。对于经肾脏消除的新抗凝药物治疗的 AF 患者,应在临床实践中实施肾功能监测。

相似文献

1
Glomerular filtration rate in patients with atrial fibrillation on warfarin treatment: a subgroup analysis from the AURICULA registry in Sweden.华法林治疗的心房颤动患者的肾小球滤过率:来自瑞典 AURICULA 登记处的亚组分析。
Thromb Res. 2011 Oct;128(4):341-5. doi: 10.1016/j.thromres.2011.04.022. Epub 2011 May 28.
2
Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).肾小球滤过率估计值对接受维生素 K 拮抗剂治疗的非常老年患者出血风险的影响。EPICA 研究代表 FCSA(意大利抗凝临床学会)的结果。
Thromb Haemost. 2012 Jun;107(6):1100-6. doi: 10.1160/TH11-10-0721. Epub 2012 Apr 26.
3
Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.达比加群酯与华法林在伴有基线肾功能异常的房颤患者中的疗效和安全性比较:RE-LY(随机评估长期抗凝治疗)试验分析。
Circulation. 2014 Mar 4;129(9):961-70. doi: 10.1161/CIRCULATIONAHA.113.003628. Epub 2013 Dec 9.
4
Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.预测房颤患者在住院环境中使用华法林的因素。
Am J Cardiovasc Drugs. 2010;10(1):37-48. doi: 10.2165/11318870-000000000-00000.
5
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA.瑞典的抗凝控制:来自国家质量登记处 AuriculA 的治疗范围内时间、大出血和血栓栓塞并发症的报告。
Eur Heart J. 2011 Sep;32(18):2282-9. doi: 10.1093/eurheartj/ehr134. Epub 2011 May 26.
6
Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial.醛固酮受体拮抗剂与伴有左心室功能障碍的心房颤动患者的心血管死亡率:来自心房颤动和充血性心力衰竭试验的观察。
Circ Heart Fail. 2012 Sep 1;5(5):586-93. doi: 10.1161/CIRCHEARTFAILURE.111.965160. Epub 2012 Jul 12.
7
Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study.比较使用 CKD-EPI 和 MDRD 研究 GFR 估算方程的 CKD 患病率和死亡率风险:AusDiab(澳大利亚糖尿病、肥胖和生活方式)研究。
Am J Kidney Dis. 2010 Apr;55(4):660-70. doi: 10.1053/j.ajkd.2009.12.011.
8
Effect of edaravone on the estimated glomerular filtration rate in patients with acute ischemic stroke and chronic kidney disease.依达拉奉对伴有慢性肾脏疾病的急性缺血性脑卒中患者估算肾小球滤过率的影响。
J Stroke Cerebrovasc Dis. 2011 Mar-Apr;20(2):111-6. doi: 10.1016/j.jstrokecerebrovasdis.2009.11.008. Epub 2010 Jun 26.
9
The practical implications of using standardized estimation equations in calculating the prevalence of chronic kidney disease.使用标准化估计方程计算慢性肾脏病患病率的实际意义。
Nephrol Dial Transplant. 2008 Feb;23(2):542-8. doi: 10.1093/ndt/gfm599. Epub 2007 Sep 22.
10
Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation.华法林、肾功能障碍与心房颤动患者急性心肌梗死后的结局。
JAMA. 2014 Mar 5;311(9):919-28. doi: 10.1001/jama.2014.1334.

引用本文的文献

1
Non-Vitamin K Oral Anticoagulants Assessment in High Risk of Bleeding Patients with Non-Valvular Atrial Fibrillation.非维生素K口服抗凝剂在非瓣膜性心房颤动高出血风险患者中的评估
Geriatrics (Basel). 2022 Feb 17;7(1):20. doi: 10.3390/geriatrics7010020.
2
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.根据肾功能分层的心房颤动患者中,多非利特与安慰剂的疗效和安全性:EURIDIS-ADONIS 试验的事后分析。
Clin Cardiol. 2022 Jan;45(1):101-109. doi: 10.1002/clc.23765. Epub 2022 Jan 12.
3
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.
达诺酮与安慰剂用于不同肾功能的心房颤动或心房扑动患者:ATHENA试验的事后分析
Eur Heart J Cardiovasc Pharmacother. 2022 Jun 8;8(4):363-371. doi: 10.1093/ehjcvp/pvab090.
4
[Anticoagulation in geriatric patients with atrial fibrillation : With what and for whom no more?].[老年房颤患者的抗凝治疗:用什么药以及不再适用于哪些人?]
Herz. 2018 May;43(3):214-221. doi: 10.1007/s00059-017-4665-z.
5
[New oral anticoagulants for prophylaxis of stroke : Results of an expert conference on practical use in geriatric patients].用于预防中风的新型口服抗凝剂:老年患者实际应用专家会议结果
Z Gerontol Geriatr. 2016 Jul;49(5):460-1. doi: 10.1007/s00391-016-1095-0.
6
Renal function in atrial fibrillation patients switched from warfarin to a direct oral anticoagulant.从华法林转换为直接口服抗凝剂的心房颤动患者的肾功能
J Thromb Thrombolysis. 2016 Nov;42(4):566-72. doi: 10.1007/s11239-016-1377-9.
7
Concerns regarding the use of dabigatran for stroke prevention in atrial fibrillation.对达比加群酯用于房颤卒中预防的担忧。
Pharmaceuticals (Basel). 2012 Feb 3;5(2):155-68. doi: 10.3390/ph5020155.